Ratings Novoray Corporation

Equities

688300

CNE100003PN0

End-of-day quote Shanghai S.E. 06:00:00 2024-07-14 pm EDT 5-day change 1st Jan Change
53.67 CNY +4.48% Intraday chart for Novoray Corporation +13.83% +1.36%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • With an expected P/E ratio at 41.77 and 30.54 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Commodity Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
+1.36% 1.32B -
+1.91% 104B
A-
-7.19% 62.15B
A-
+84.76% 50.92B
B
+6.22% 36.09B
B
+0.60% 30.95B
A-
+4.57% 18.85B
B-
+18.55% 17.61B
C+
+8.96% 13.97B
B-
+76.66% 13B
B-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 688300 Stock
  4. Ratings Novoray Corporation